Critical Analysis: Imris (OTCMKTS:IMRSQ) & iRadimed (NASDAQ:IRMD)

iRadimed (NASDAQ:IRMD – Get Free Report) and Imris (OTCMKTS:IMRSQ – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Profitability

This table compares iRadimed and Imris’ net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and target prices for iRadimed and Imris, as provided by MarketBeat.

iRadimed currently has a consensus price target of $120.00, suggesting a potential upside of 27.00%. Given iRadimed’s stronger consensus rating and higher probable upside, research analysts plainly believe iRadimed is more favorable than Imris.

Insider and Institutional Ownership

92.3% of iRadimed shares are held by institutional investors. 34.6% of iRadimed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares iRadimed and Imris”s gross revenue, earnings per share (EPS) and valuation.

iRadimed has higher revenue and earnings than Imris.

Summary

iRadimed beats Imris on 10 of the 10 factors compared between the two stocks.

About iRadimed

(Get Free Report)

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

About Imris

(Get Free Report)

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Its VISIUS Surgical Theatre incorporates magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites to provide intraoperative imaging for specific medical applications by bringing advanced imaging into the operating room (OR). The company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular, and cardiovascular markets. It also provides service and extended maintenance contracts, and accessories and disposables. The company was founded in 2005 and is based in Winnipeg, Canada.